Context: The regulation of TSH bioactivity in humans is not completely understood.
COMMENT
The bioactivity of serum TSH is classically investigated by determining the B/I ratio of TSH, i.e. the ratio between bioactive (B) TSH and immunoassayable (I) TSH. This method was refined by the group of Paolo Beck-Peccoz and allowed these authors to show (Persani et al., JCEM 83:2486 , 1998 that the bioactivity of serum TSH was reduced in hypothyroid patients and increased after l-T4 administration. Mature TSH is a glycoprotein hormone containing complex bi-& tri-antennary carbohydrate structures, with terminal sulfate & sialic acid residues. With affinity chromatography (concanavalin A), the degree of TSH sialylation can be determined. In the JCEM 1998 article alluded to above, the authors showed that circulating TSH was more heavily sialylated in hypothyroid patients, compared to normal. In the present work, not only were these earlier results confirmed but, in addition, the authors were able to show that serum TSH bioactivity was directly correlated to serum T 3 concentrations and their rapid and marked changes after l-T4 administration in hypothyroid patients. The correlation was surprisingly strong (r = 0.80), but one should remember that the study was carried out in severely hypothyroid patients, with a mean TSH of 136 µU/ml and a mean serum free T 4 & total T 3 (before treatment) of 2.7 pmol/L and 0.5 nmol/L, respectively. What does it all mean and what do we learn from this interesting study? First, the data confirmed the notion that the biological properties of circulating isoforms of serum TSH vary in pathological states and that the high TSH levels characteristic of primary hypothyroidism may represent an adaptive mechanism aiming at adjusting temporarily the thyroid stimulating activity of TSH (longer half-life with reduced bioactivity). Thus, primary hypothyroidism is associated with the secretion of highly sialylated TSH with a reduced intrinsic biological activity. Second, the study of TSH bioactivity in patients with rapidly changing thyroid hormone levels (after l-T4 administration) provides an assessment of the role of hypothalamic TRH in these processes, suggesting that the role of high TRH is probably relatively minor compared to that of thyroid hormones. Third, we should keep in mind that in clinical practice our reasoning on thyroid function tests is often based on absolute serum TSH levels but does not take into account possible variations in TSH bioactivity. In the present study for instance, the authors found a negative correlation in the normal controls between TSH bioactivity and age (between 28 and 52 years). Fourth and finally, a "finalistic" interpretation of present data remains difficult. In a clinical state with "low thyroid hormone/high TRH" (i.e. primary hypothyroidism), it is understandable that "nature" has favoured elevated TSH levels in order to help restore more normal thyroid hormone levels (this is the basis for a physiologic feed-back mechanism of a "thyrostat"). However, why "nature" would have favoured at the same time the presence of a less bioactive TSH with a prolonged half-life is difficult to comprehend, although the notion that the resulting secretion product of TSH action (namely, thyroid hormones produced by the thyroid) somehow regulates positively its own regulator has something appealing, albeit still mysterious. 
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